Silmälääkäripalvelut Pöllönen & Timgren Oy is a limited company based in Turku, registered in 2007. In the financial year ending 31.12.2025, revenue was 460 t€ and operating profit 34 t€; equity ratio 96.5 %. Its taxable income in 2024 was 84 t€ and its income taxes 17 t€.
Revenue 2025460 t€-5 % on the previous year
Operating profit34 t€7,4 % of revenue
Net profit39 t€EBITDA 21 t€
Equity ratio96,5 %quick ratio 8,69
Taxable income 202484 t€
upper half of its industry
Income taxes 202417 t€76 t€ in 2020–2024
In business18 yrsregistered 31.12.2007
Turku: 44 new companies in 30 days
- Grass Physio & Performance OyFysioterapiapalvelut
- Cratos Trading Limited OyMuualla luokittelematon kaikki muu monenlainen ammatillinen, tieteellinen ja tekninen toiminta
- Gendent OyHammasproteesien ja -implanttien valmistus
Try for free
Get your area's new companies by email every morning. 14 days, no card needed.
Financials
RevenueOperating profitNet profit
| Key figures | 31.12.2025 | 31.12.2024 | 31.12.2023 |
|---|---|---|---|
| Revenue | 460 t€ | 486 t€ | 459 t€ |
| Revenue change | -5,4 % | 5,9 % | – |
| EBITDA | 21 t€ | 76 t€ | 56 t€ |
| EBITDA % | 4,5 % | 15,7 % | 12,2 % |
| Operating profit | 34 t€ | 75 t€ | 55 t€ |
| Operating margin | 7,4 % | 15,5 % | 11,9 % |
| Net profit | 39 t€ | 25 t€ | 40 t€ |
| Personnel costs | -311 t€ | 300 t€ | 300 t€ |
| Equity ratio | 96,5 % | 95,9 % | 97,1 % |
| Quick ratio | 8,69 | 8,20 | 9,45 |
| Current ratio | 8,69 | 8,20 | 9,45 |
| Debt to revenue | 2,8 % | 3,0 % | 2,2 % |
| Return on equity | 11,2 % | 7,3 % | 11,6 % |
| Balance sheet total | 365 t€ | 358 t€ | 356 t€ |
| Equity | 352 t€ | 343 t€ | 346 t€ |
| Cash and bank | 91 t€ | 94 t€ | 72 t€ |
Balance sheet
Balance sheet totalEquityCash
Income statement and balance sheet
Income statement
| 31.12.2025 | 31.12.2024 | 31.12.2023 | |
|---|---|---|---|
| Turnover | 460 t€ | 486 t€ | 459 t€ |
| Other operating income | – | 0 € | 486 € |
| Personnel expenses | 311 t€ | -300 t€ | -300 t€ |
| Depreciations and reductions in value | 14 t€ | -740 € | -986 € |
| Other operating expenses | 101 t€ | -109 t€ | -104 t€ |
| Operating profit (loss) | 34 t€ | 75 t€ | 55 t€ |
| Financial income and expenses + (-) | -14 t€ | -34 t€ | -4 118 € |
| Profit (loss) before appropriations and taxes | 48 t€ | 42 t€ | 51 t€ |
| Income taxes | 8 831 € | -17 t€ | -11 t€ |
| Profit (loss) for the financial year | 39 t€ | 25 t€ | 40 t€ |
Balance sheet
| 31.12.2025 | 31.12.2024 | 31.12.2023 | |
|---|---|---|---|
| Non-current assets | 260 t€ | 245 t€ | 268 t€ |
| Receivables | 14 t€ | 20 t€ | 15 t€ |
| Cash in hand and at banks | 91 t€ | 94 t€ | 72 t€ |
| Current assets | 105 t€ | 113 t€ | 88 t€ |
| Assets | 365 t€ | 358 t€ | 356 t€ |
| Share capital or other similar capital | 5 000 € | 5 000 € | 5 000 € |
| Capital and reserves | 352 t€ | 343 t€ | 346 t€ |
| Long-term liabilities | 717 € | 717 € | 950 € |
| Short-term liabilities | 12 t€ | 14 t€ | 9 262 € |
| Liabilities | 13 t€ | 15 t€ | 10 t€ |
All financial statement items (42)
| 31.12.2025 | 31.12.2024 | 31.12.2023 | |
|---|---|---|---|
| Turnover | 460 t€ | 486 t€ | 459 t€ |
| Other operating income | – | 0 € | 486 € |
| Personnel expenses | 311 t€ | -300 t€ | -300 t€ |
| Depreciations and reductions in value | 14 t€ | -740 € | -986 € |
| Other operating expenses | 101 t€ | -109 t€ | -104 t€ |
| Operating profit (loss) | 34 t€ | 75 t€ | 55 t€ |
| Financial income and expenses + (-) | -14 t€ | -34 t€ | -4 118 € |
| Profit (loss) before appropriations and taxes | 48 t€ | 42 t€ | 51 t€ |
| Income taxes | 8 831 € | -17 t€ | -11 t€ |
| Profit (loss) for the financial year | 39 t€ | 25 t€ | 40 t€ |
| Non-current assets | 260 t€ | 245 t€ | 268 t€ |
| Receivables | 14 t€ | 20 t€ | 15 t€ |
| Cash in hand and at banks | 91 t€ | 94 t€ | 72 t€ |
| Current assets | 105 t€ | 113 t€ | 88 t€ |
| Assets | 365 t€ | 358 t€ | 356 t€ |
| Share capital or other similar capital | 5 000 € | 5 000 € | 5 000 € |
| Capital and reserves | 352 t€ | 343 t€ | 346 t€ |
| Long-term liabilities | 717 € | 717 € | 950 € |
| Short-term liabilities | 12 t€ | 14 t€ | 9 262 € |
| Liabilities | 13 t€ | 15 t€ | 10 t€ |
| Investments | 219 t€ | 242 t€ | 265 t€ |
| Other short-term receivables | 8 € | 6 100 € | 0 € |
| Other current liabilities | 9 517 € | 8 075 € | 7 700 € |
| Retained earnings | 307 t€ | 313 t€ | 300 t€ |
| Short-term prepayments and accrued income | 14 t€ | 13 t€ | 5 919 € |
| Short-term sales receivables | – | 0 € | 9 486 € |
| Profit (loss) for the period, equity | 39 t€ | 25 t€ | 40 t€ |
| Short-term receivables | 14 t€ | 20 t€ | 15 t€ |
| Interest expenses and other financial expenses for non-Group companies | 1 616 € | -100 € | -2 € |
| Tangible assets | 41 t€ | 2 219 € | 2 959 € |
| Wages and salaries | 217 t€ | -212 t€ | -218 t€ |
| Short-term accrued expenses and deferred income | 2 506 € | 5 713 € | 1 562 € |
| Liabilities | 365 t€ | 358 t€ | 356 t€ |
| Other interest and financial income from non-group companies | 142 € | 124 € | 16 € |
| Other social security expenses | 9 290 € | -6 542 € | -29 t€ |
| Machinery and equipment | 41 t€ | 2 219 € | 2 959 € |
| Impairment on investments for non-current assets | 1 618 € | -42 t€ | -12 t€ |
| Depreciations according to plan | 14 t€ | -740 € | -986 € |
| Other shares and similar rights of ownership | 219 t€ | 242 t€ | 265 t€ |
| Pension expenses | 84 t€ | -82 t€ | -53 t€ |
| Income from other investments under non-current assets, from other companies | 17 t€ | 8 493 € | 7 576 € |
| Other long-term liabilities | 717 € | 717 € | 950 € |
From financial statements filed digitally (XBRL) with the Finnish Patent and Registration Office; ratios calculated from them. Equity ratio = (equity + accumulated appropriations) / (balance sheet total − advances received).
Taxes
Measured by taxable income, Silmälääkäripalvelut Pöllönen & Timgren Oy is in the upper half of the industry class medical specialists activities (2077 companies with taxable income; median 81 t€).
Taxable income is the profit as calculated for taxation, not revenue. Public data from the Finnish Tax Administration; figures for 2025 are published in November 2026.